podcasting Archives - AudioMedica.com

Tagged: podcasting

- in News
- — 8 Jan, 2008
Early Breast Cancer Chemotherapy: Long Term Findings

Richard Peto
REFERENCE: Lancet 371:29-40; January 5, 2008
RICHARD PETO, Oxford University
The prospect of cutting breast cancer mortality in half throughout the world is held out by Richard Peto of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). He
…
Read more
- in General Medicine
- — 4 Jan, 2008
Non Drug Intervention: Better Than Antipsychotic Drugs for Aggressive Challenging Behaviour in Intellectual Disability

Peter Tyrer
REFERENCE: Lancet 371:57 January 5, 2008
PETER TYRER, Imperial College, W6 8RP London
A randomized study comparing treatment with risperidone, or haloperidol, or placebo to treat patients who have intellectual disability presenting with a syndrome commonly labelled as
…
Read more
- in Oncology
- — 15 Dec, 2007
ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up

Jack Cuzick
JACK CUZICK, Wolfson Institute of Preventive Medicine, London
New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continued superiority of the aromatase inhibitor. Among other things, the data
…
Read more
- in Oncology
- — 15 Dec, 2007
New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer

Jose Baselga
JOSE BASELGA, Vall d’Hebron Hospital, Barcelona
RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The investigators saw more responses in the experimental arm, and
…
Read more
- in Oncology
- — 11 Dec, 2007
Live Report from ASH:
Ibritumomab Provides Benefit in Patients with Follicular Lymphoma

Anton Hagenbeek
ANTON HAGENBEEK, University Medical Centre Utrecht
For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study author Anton Hagenbeek at the ASH
…
Read more
- in Oncology
- — 11 Dec, 2007
Live Report from ASH:
Can Intensive Immunochemotherapy Cure Mantle Cell Lymphoma?

Christian Geisler
CHRISTIAN GEISLER, Rigshospitalet, Copenhagen
Mantle cell lymphoma, which was previously considered incurable, has apparently been cured in some patients on a phase II study. Derek Thorne got the details on the study – which featured an intensive immunochemotherapy
…
Read more
- in Oncology
- — 10 Dec, 2007
Live Report from ASH:
Oblimersen Extends Survival in Chronic Lymphocytic Leukemia

Susan O’Brien
SUSAN O’BRIEN, MD Anderson Cancer Center, Houston
For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy. Susan O’Brien presented data from this phase III trial to the American Society of Hematology
…
Read more
- in Oncology
- — 10 Dec, 2007
Live Report from ASH:
Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML

Richard Stone
RICHARD STONE, Dana-Farber Cancer Institute, Boston
GEORGE CANELLOS, Dana-Farber Cancer Institute
New data shows that dasatinib is giving durable responses in patients with chronic phase chronic myeloid leukemia who have failed, or who cannot tolerate imatinib. So where
…
Read more
- in Oncology
- — 10 Dec, 2007
Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes

Pierre Fenaux
PIERRE FENAUX, Paris 13 University
Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with high-risk MDS. Pierre Fenaux of Paris 13 University
…
Read more
- in Oncology
- — 10 Dec, 2007
Live Report from ASH:
Interleukin-2 For Acute Myeloid Leukemia In First Remission?

Jonathan Kolitz
JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY
GEORGE CANELLOS, Dana-Farber Cancer Institute
For patients with acute myeloid leukemia in first remission, new data suggests that there may be a benefit from interleukin-2. Derek Thorne got the interim
…
Read more
- in General Medicine
- — 9 Dec, 2007
New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura

Terry Gernsheimer
TERRY GERNSHEIMER, University of Washington Medical Center, Seattle
An investigational drug AMG 531 has increased and sustained platelet counts in splenectomized patients with chronic immune thrombocytopenic purpura or ITP. This was in a placebo controlled phase III trial
…
Read more
- in Public Health
- — 9 Dec, 2007
No Use Of Hydroxyurea In Country With Most Sickle Cell Anemia

Zakari Aliyu
REFERENCE: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta
ZAKARI ALIYU, Howard University, Washington DC
Nigeria has the highest incidence of sickle cell anemia in the world, with over 150,000 children being born each year with
…
Read more

Tagged: podcasting

Sign up for AudioMedica.com news